Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tg Therapeutics (TGTX) Invested Capital (2016 - 2025)

Historic Invested Capital for Tg Therapeutics (TGTX) over the last 10 years, with Q3 2025 value amounting to $607.2 million.

  • Tg Therapeutics' Invested Capital rose 21600.1% to $607.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $607.2 million, marking a year-over-year increase of 21600.1%. This contributed to the annual value of $222.4 million for FY2024, which is 1477.2% down from last year.
  • As of Q3 2025, Tg Therapeutics' Invested Capital stood at $607.2 million, which was up 21600.1% from $276.4 million recorded in Q2 2025.
  • Tg Therapeutics' Invested Capital's 5-year high stood at $607.2 million during Q3 2025, with a 5-year trough of $27.4 million in Q1 2023.
  • For the 5-year period, Tg Therapeutics' Invested Capital averaged around $233.8 million, with its median value being $222.4 million (2024).
  • Per our database at Business Quant, Tg Therapeutics' Invested Capital soared by 3523762.01% in 2021 and then tumbled by 8389.95% in 2023.
  • Quarter analysis of 5 years shows Tg Therapeutics' Invested Capital stood at $238.1 million in 2021, then crashed by 75.4% to $58.6 million in 2022, then soared by 345.33% to $260.9 million in 2023, then dropped by 14.77% to $222.4 million in 2024, then soared by 173.07% to $607.2 million in 2025.
  • Its Invested Capital stands at $607.2 million for Q3 2025, versus $276.4 million for Q2 2025 and $237.3 million for Q1 2025.